Isoniazid-induced Lupus: When the Cure Can Be Lethal.
drug-induced-lupus
idiosyncratic reaction
isoniazid
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
18 Mar 2020
18 Mar 2020
Historique:
entrez:
22
4
2020
pubmed:
22
4
2020
medline:
22
4
2020
Statut:
epublish
Résumé
A 50-year-old female with a past medical history of bone tuberculosis diagnosed nine months ago was admitted in our infirmary for persistent fever with no evident cause. The patient was treated with isoniazid, rifampicin, pyrazinamide, and ethambutol for seven months and for the past two months, she was taking isoniazid and rifampicin. She went to our emergency room (ER) for back pain and fever that she had been experiencing for the last month. She was admitted with suspicion of disseminated tuberculosis that was never confirmed. Physical examination was unremarkable. Blood tests showed an elevation of inflammation parameters. A computed tomography (CT) scan of the chest showed a mild pleural effusion. She remained with fever during the three weeks in the infirmary while undergoing many other studies that were all negative. The back pain would change sides, and three consecutive thoracic radiographies showed a small-sized pleural effusion that was either predominantly right-sided or left-sided. Several differential diagnoses were considered in the process, namely an active infection, neoplasia, or autoimmune disease. The search for circulating lupus anticoagulant was positive. Antinuclear antibodies (ANA) were positive and the anti-histone antibody was strongly positive. At this point, we suspected a drug-induced lupus diagnosis, and isoniazid was discontinued. Following discontinuation of isoniazid, back pain and fever subsided and patient was discharged after one week. This case is a diagnostic challenge because of the rarity and symptom severity of isoniazid-induced lupus. Isoniazid rarely induced this lupus-like syndrome, with an incidence of considerably less than 1%.
Identifiants
pubmed: 32313752
doi: 10.7759/cureus.7311
pmc: PMC7164554
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e7311Informations de copyright
Copyright © 2020, Cerqueira et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Drug Saf Case Rep. 2019 Sep 20;6(1):7
pubmed: 31541371
Actas Dermosifiliogr. 2014 Jan-Feb;105(1):18-30
pubmed: 23164669
Drug Metab Dispos. 1992 Mar-Apr;20(2):205-10
pubmed: 1352211
Am J Ther. 2002 Mar-Apr;9(2):163-5
pubmed: 11897931
Pan Afr Med J. 2018 Apr 06;29:200
pubmed: 30061978
Toxicology. 2005 Apr 15;209(2):135-47
pubmed: 15767026
Curr Med Chem. 2019 Apr 04;:
pubmed: 30947650
Cureus. 2017 Sep 7;9(9):e1661
pubmed: 29147636
Pan Afr Med J. 2015 Feb 27;20:181
pubmed: 26430478
Lupus. 2006;15(11):757-61
pubmed: 17153847